D70.1
Agranulocytosis secondary to cancer chemotherapy
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T45.1X5)
Code Also
- underlying neoplasm
Medical Intelligence & Overview
Agranulocytosis secondary to cancer chemotherapy is a serious condition characterized by a marked decrease in granulocytes, a type of white blood cell essential for fighting infections. This condition officially falls under the ICD-10 code D70.1 and occurs as a complication of certain cancer treatments. Its development can pose significant health risks, including increased susceptibility to infections and complications related to immune deficiency. Understanding its causes, symptoms, and management options can help in early recognition and care.
Causes & Symptoms
Clinical Causes: Use of chemotherapy drugs that suppress bone marrow activity, leading to decreased production of granulocytes. Certain antibiotics and other medications used concurrently during cancer treatment that may also contribute to bone marrow suppression. Underlying bone marrow disorders that can be exacerbated by chemotherapy.
Key Symptoms: Frequent or severe infections due to low white blood cell counts. Fever and chills, often indicating infection. Sore throat and mouth ulcers. Weakness and fatigue. Pallor and signs of anemia. Bleeding or bruising due to low platelet counts (may accompany some-related blood disorders).
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves blood tests that reveal a significant reduction in granulocytes, especially neutrophils. A complete blood count (CBC) with differential is essential for confirming neutropenia. Additional tests may include bone marrow biopsy to assess marrow activity and rule out other marrow-involving conditions. A thorough review of medication history, especially recent chemotherapy regimens, is also crucial.
Treatment Protocols: Discontinuation or modification of the causative chemotherapy agents under medical supervision. Use of growth factors such as granulocyte colony-stimulating factor (G-CSF) to stimulate white blood cell production. Infection prevention measures including strict hygiene, isolation during infection episodes, and prompt treatment of any infections with antibiotics. Supportive care like blood transfusions if anemia is present. Monitoring blood counts regularly to assess recovery and detect potential complications early.
Clinical Advice & FAQs
Billing Guidance
Is D70.1 a billable ICD-10 code?
Yes, D70.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D70.1?
Clinical documentation must specify the nature of Agranulocytosis secondary to cancer chemotherapy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference